ADEKVAT GIPOGLIKEMIK TERAPIYA IMKONIYATLARI YORDAMIDA ELEKTRIK BEQAROR MIOKARD KORREKSIYASI
##article.subject##:
gipoglikemik terapiya, qandli diabet, glikirlangan gemoglobin, bo’lmachalar fibrillatsiyasi##article.abstract##
Ushbu maqolada biz uzoq muddatli EKG monitoringi va FreeStyle Libre yordamida qandli diabet bilan og'rigan bemorlarda bazal insulin Degludekni boshqa antigiperglikemik dorilar bilan birgalikda qo'llash bo'yicha o'z natijalarimizni yoritdik. Glikirlangan gemoglobin darajasi yaxshi bo'lgan bemorimizda CGM ma'lumotlariga ko'ra bo’lmachalar fibrillatsiyaning paroksizmalari bilan bog'liq bo'lgan gipoglikemiyaning tez-tez epizodlari kuzatildi. Ushbu holat terapiyani qayta ko'rib chiqish masalasini hal qilish foydasiga guvohlik berdi. Shunday qilib, biz Glargin bazal insulini yangi avlod Degludek insulini bilan almashtirdik, bu esa glyukemik o'zgaruvchanlikka aniqroq ta'sir qiladi, shuning uchun uning ta'siri oldindan taxmin qilinadi. Hozirgi vaqtda o'limga olib keladigan aritmiyalar paydo bo'lishi bilan miyokardning elektr beqarorligini rivojlanishiga gipoglikemiya ta'sirining ishonchli dalillari mavjud. Glikemiya va yurak urish tezligini sinxron ravishda uzoq muddatli kuzatish tizimlaridan foydalanish gipoglikemiya epizodlarini aniqroq qayd etish va insulin terapiyasini to'g'rilashga imkon beradi va shu bilan aritmiya xavfini kamaytiradi.
Библиографические ссылки
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32(1):193–203 DOI: http://dx.doi.org/10.2337/dc08-9025
Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetic Medicine. 2012;29(5):682–689
Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-2559. Epub 2008 Jun 6.
Campbell IW. Dead in bed syndrome: a new manifestation of nocturnal hypoglycaemia? Diabet Med. 1991 Jan;8(1):3-4. 12. Tattersall RB, Gill GV. Unexplained deaths of type 1 diabetic patients. Diabet Med. 1991 Jan;8(1):49-5
Gough SCL, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low-Volume Insulin Degludec 200 Units/ mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial. Diabetes Care. 2013;36(9):2536–2542. DOI: http://dx.doi.org/10.2337/dc12-2329
Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, et al. Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long. Diabetes Care. 2012;35(12):2464–2471. DOI: http://dx.doi.org/10.2337/dc12-1205
FAS, full analysis set; NAS, non-randomized analysis set; LOCF, last observation carried forward IAsp, insulin aspart; IDeg, insulin degludec; LIRA, liraglutide Comparisons: Estimates adjusted for multiple covariates Mathieu C et al. Diabetes, obesity & metabolism. 2014;16:636-644.
Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357(17):1716- 1730. doi: 10.1056/NEJMoa075392
Riddle M, Umpierrez G, DiGenio A, et al. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34(12):2508-2514. doi: 10.2337/dc11-0632
Ahren B. Beta- and alpha-cell dysfunction in subjects developing impaired glucose tolerance: outcome of a 12-year prospective study in postmenopausal Caucasian women. Diabetes. 2009;58(3):726-731. doi: 10.2337/db08-1158
Zinman B, Gerich J, Buse J, et al. American Diabetes Association. Standards of medical care in diabetes-2010 (vol 33, pg S11, 2010). Diabetes care. 2010;33(3):692-692.
